CN116801867A - 利地利唑的固体片剂剂型 - Google Patents

利地利唑的固体片剂剂型 Download PDF

Info

Publication number
CN116801867A
CN116801867A CN202280010065.7A CN202280010065A CN116801867A CN 116801867 A CN116801867 A CN 116801867A CN 202280010065 A CN202280010065 A CN 202280010065A CN 116801867 A CN116801867 A CN 116801867A
Authority
CN
China
Prior art keywords
riluzole
tablet
tetrahydrate
tablet formulation
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280010065.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·X·威尔逊
L·特雷斯皮迪
J-F·卡尼奥
P·蒂明斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit (oxford) Ltd
Original Assignee
Summit (oxford) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit (oxford) Ltd filed Critical Summit (oxford) Ltd
Publication of CN116801867A publication Critical patent/CN116801867A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280010065.7A 2021-01-14 2022-01-14 利地利唑的固体片剂剂型 Pending CN116801867A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
GB2100470.0 2021-01-14
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (1)

Publication Number Publication Date
CN116801867A true CN116801867A (zh) 2023-09-22

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280010065.7A Pending CN116801867A (zh) 2021-01-14 2022-01-14 利地利唑的固体片剂剂型

Country Status (12)

Country Link
US (1) US12318487B2 (https=)
EP (1) EP4277604A1 (https=)
JP (1) JP2024503689A (https=)
KR (1) KR20230131253A (https=)
CN (1) CN116801867A (https=)
AU (1) AU2022207756B2 (https=)
CA (1) CA3145677A1 (https=)
GB (1) GB202100470D0 (https=)
IL (1) IL304354A (https=)
MX (1) MX2023008249A (https=)
WO (1) WO2022153246A1 (https=)
ZA (1) ZA202306739B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196468A1 (en) * 2007-07-11 2010-08-05 Pierre Fabre Medicament Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
US20120282336A1 (en) * 2009-11-13 2012-11-08 Astrazeneca Uk Limited Bilayer tablet formulations
US20160184283A1 (en) * 2008-12-02 2016-06-30 Summit Therapeutics Plc Antibacterial compounds
CN111315736A (zh) * 2017-10-05 2020-06-19 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016042A1 (de) 1994-11-17 1996-05-30 F. Hoffmann-La Roche Ag Antibakterielle dibenzimidazol-derivate
HUP0303494A3 (en) 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
DE60309701T2 (de) 2002-06-13 2007-09-06 Vertex Pharmaceuticals Inc., Cambridge 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
WO2004041209A2 (en) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
AU2006311729A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
ES2568455T3 (es) 2010-06-01 2016-04-29 Summit Therapeutics Plc Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
IL310920A (en) * 2015-01-27 2024-04-01 Janssen Pharmaceutica Nv Dispersible compositions
KR20190140011A (ko) * 2017-04-28 2019-12-18 아사나 바이오사이언시스 엘엘씨 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
KR20210033483A (ko) * 2018-07-19 2021-03-26 다케다 야쿠힌 고교 가부시키가이샤 Cdc7 억제제를 갖는 약제학적 조성물
KR102737283B1 (ko) 2019-07-17 2024-12-03 서밋 (옥스포드) 리미티드 리디닐라졸 및 이의 결정 형태의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196468A1 (en) * 2007-07-11 2010-08-05 Pierre Fabre Medicament Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
US20160184283A1 (en) * 2008-12-02 2016-06-30 Summit Therapeutics Plc Antibacterial compounds
US20120282336A1 (en) * 2009-11-13 2012-11-08 Astrazeneca Uk Limited Bilayer tablet formulations
CN111315736A (zh) * 2017-10-05 2020-06-19 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
屠美: "药用高分子材料及其应用", 30 November 2006, 华南理工大学出版社, pages: 28 - 29 *
李津明: "现代制药技术", 30 April 2005, 中国医药科技出版社, pages: 10 - 11 *

Also Published As

Publication number Publication date
AU2022207756A9 (en) 2024-05-09
AU2022207756B2 (en) 2026-01-15
IL304354A (en) 2023-09-01
MX2023008249A (es) 2023-07-26
US20220226249A1 (en) 2022-07-21
AU2022207756A1 (en) 2023-07-27
ZA202306739B (en) 2025-05-28
US12318487B2 (en) 2025-06-03
GB202100470D0 (en) 2021-03-03
CA3145677A1 (en) 2022-07-14
JP2024503689A (ja) 2024-01-26
EP4277604A1 (en) 2023-11-22
KR20230131253A (ko) 2023-09-12
WO2022153246A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
KR101931209B1 (ko) Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
US20220339111A1 (en) Immediate-release tablets containing a drug and processes for forming the tablets
KR20100063090A (ko) 알리스키렌 및 발사르탄의 생약 제제
KR20230134560A (ko) 약학적 조성물
JP2020114834A (ja) セリチニブ製剤
US12318487B2 (en) Solid tablet dosage form of ridinilazole
WO2023213878A1 (en) Solid tablet dosage form of ridinilazole
WO2007141806A1 (en) Pharmaceutical formulations comprising oxcarbazepine and methods thereof
CN106511291A (zh) 一种盐酸阿考替胺缓释片剂及其制备方法
WO2024079245A1 (en) Ridinilazole for treating clostridium difficile
HK40099995A (en) Immediate-release tablets containing a drug and processes for forming the tablets
HK40061820A (en) Immediate-release tablets containing a drug and processes for forming the tablets
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
HK40099995B (en) Immediate-release tablets containing a drug and processes for forming the tablets
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
HK40069271B (zh) 含有药物的立即释放片剂和用於形成片剂的方法
TW201300106A (zh) 治療ｈｃｖ感染之醫藥組合物
HK1254389B (en) Immediate-release tablets containing a drug and processes for forming the tablets

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination